Sitaxentan
Sitaxentan
Sitaxentan (pronounced si-tax-en-tan) is a pharmaceutical drug that was primarily used in the treatment of pulmonary arterial hypertension (PAH). It is an endothelin receptor antagonist (ERA) that selectively blocks the endothelin A receptor.
Etymology
The name "Sitaxentan" is derived from its chemical structure. The "Sita" part of the name is derived from the Greek word "sitos", meaning food or grain, which refers to the drug's ability to block the endothelin A receptor, a protein that is often overexpressed in conditions like PAH. The "xentan" part of the name is a common suffix used in the naming of endothelin receptor antagonists.
Usage
Sitaxentan was used to treat pulmonary arterial hypertension by blocking the action of endothelin-1, a vasoconstrictive peptide. This blockage leads to the dilation of blood vessels, thereby reducing blood pressure in the pulmonary artery.
Side Effects
Common side effects of Sitaxentan included liver toxicity, peripheral edema, and anemia. Due to the risk of severe liver toxicity, the drug was withdrawn from the market worldwide in 2010.
Related Terms
- Endothelin receptor antagonist
- Pulmonary arterial hypertension
- Vasoconstrictive peptide
- Peripheral edema
- Anemia
External links
- Medical encyclopedia article on Sitaxentan
- Wikipedia's article - Sitaxentan
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski